NewAmsterdam Pharma Files 8-K
Ticker: NAMSW · Form: 8-K · Filed: May 7, 2025 · CIK: 1936258
| Field | Detail |
|---|---|
| Company | Newamsterdam Pharma CO N.V. (NAMSW) |
| Form Type | 8-K |
| Filed Date | May 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing
TL;DR
NewAmsterdam Pharma filed an 8-K on 5/7/25. Basic corporate info update.
AI Summary
NewAmsterdam Pharma Co N.V. filed an 8-K on May 7, 2025, reporting on other events and financial statements. The filing details their corporate structure and principal executive offices located in Naarden, The Netherlands.
Why It Matters
This filing provides essential corporate and financial update information for investors and stakeholders of NewAmsterdam Pharma Co N.V.
Risk Assessment
Risk Level: low — The filing is a routine corporate update and does not contain significant new financial or operational risks.
Key Players & Entities
- NewAmsterdam Pharma Co N.V. (company) — Registrant
- May 7, 2025 (date) — Date of Report
- Naarden, The Netherlands (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' for NewAmsterdam Pharma Co N.V.
When was this 8-K report filed?
This 8-K report was filed on May 7, 2025.
Where are NewAmsterdam Pharma Co N.V.'s principal executive offices located?
NewAmsterdam Pharma Co N.V.'s principal executive offices are located at Gooimeer 2-35, Naarden, The Netherlands, 1411 DC.
What is the Commission File Number for NewAmsterdam Pharma Co N.V.?
The Commission File Number for NewAmsterdam Pharma Co N.V. is 001-41562.
What was the former name of the company and when did the name change occur?
The former name of the company was NewAmsterdam Pharma Co B.V., and the date of the name change was July 1, 2022.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 7, 2025 regarding NewAmsterdam Pharma Co N.V. (NAMSW).